Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection

Authors: David P. Holland, Gillian D. Sanders, Carol D. Hamilton, Jason E. Stout

DOI: 10.1371/journal.pone.0022276

Abstract Summary

Researchers used economic modeling to evaluate rifapentine-based regimens for latent tuberculosis treatment. Daily isoniazid/rifapentine for one month proved most cost-effective, while the three-month weekly regimen also outperformed standard nine-month isoniazid therapy. Both shorter regimens remained economically viable even with reduced efficacy, supporting their advancement to large-scale clinical trials.

Why Brain? 🧠

Shorter rifapentine-based regimens for latent TB (1 month daily or 3 months weekly) could be more cost-effective than standard 9-month isoniazid treatment, warranting large-scale trials.

License: CC BY.

The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.